FDA Arthritis Advisory Committee (AAC) and Drug Safety Committees are meeting today in Hyattsville to consider the approval of nintedanib (OFEV, made by BI), for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) https://t.co/z4uLJ8hdyX